Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.7.10.2 (focal adhesion kinase)
 44,029 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In a clinical study the tolerance and efficacy of a gamma-globulin, treated at pH 4, has been studied. This preparation manufactured by the "Zentrallaboratorium des Blutspendedienstes SRK" can be given intravenously without any risk of untoward reactions. It has been applied in high dosages up to 99 g per week. In 15 cases with primary humoral immunodeficiency, the frequency and the severity of acute bacterial infections were markedly reduced or completely absent. In 16 patients without antibody deficiency but suffering from severe septic-toxic infections, results with Immunglobulin SRK were encouraging and warrant further controlled studies.
 ...
PMID:[Prevention and therapy with immunoglobulin SRK]. 3 27

For accurate evaluation of the usefulness of gamma-globulin treatment, the clinical indications for passive immune prophylaxis and immunotherapy and the specific characteristics of commercially available gamma-globulin preparations have to be considered. Detailed investigations of currently used gamma-globulin preparations have shown that as yet no ideal product is available. Classical standard gamma-globulin and, in particular, enzymatically treated (Gamma-Venin, Veinoglobuline) or chemically modified preparations (Gamma-Globulin i.v. SRK, Intraglobin) for intravenous use have some deficiencies and involve potential risks for the patient. Nor is the infusion of "fresh frozen plasma" a safe and generally applicable alternative to the use of gamma-globulin concentrates. Thus from the outset the preconditions for effective treatment with gamma-globulin are not optimal. Standard and hyperimmune preparations, given once intramuscularly, are suitable for the prophylaxis of viral and bacteriotoxic diseases. In patients apt to react abnormally it is important to distinguish clearly between the few accepted indications and those that are more doubtful. Anti-D immunoglobulin is essential for the prevention of Rhesus sensitization after the delivery of a Rhesus-positive child. In general, gamma-globulin is recommended for substitution therapy and for the prophylaxis of recurrent acute bacterial infections in patients suffering from transient, congenital and acquired antibody-deficiency states. In such cases, high doses of an intravenously administrable preparation with a relatively long biologic half-life are recommended. The evidence for the effectiveness of gamma-globulin treatment of bacterial infections in patients without manifest disturbance of humoral immunity is equivocal. This is true, for example, of the oft-recommended combined use of antibiotics and high doses of intravenous gamma-globulin which is said to provide optimum antibacterial and antitoxic protection. There is even less chance of obtaining beneficial effects if gamma-globulin is given as an "ultimo ratio" in severe generalized bacterial infections resistant to antibiotic treatment. Localized and predominantly chronic infections are barely influenced by gamma-globulin. It is still too early to make a final assessment regarding the place and value of immunoglobulin concentrates for prophylactic and therapeutic purposes. This will only be possible if a preparation becomes available which contains all immunoglobulins in a biologically optimum state and concentration, is well tolerated and can be given in adequate doses both intramuscularly and intravenously.
 ...
PMID:[Prophylaxis and therapy with gamma globulin. General characterization and clinical use of gamma globulin preparations]. 6 93

12 patients with secondary antibody deficiency syndrome received a new gammaglobulin compound intravenously (lyoph. SRK Sandoz). The drug was given in a 3% NaCl-solution once to four times. At the end of the infusion of 6 g gammaglobulin and after one week, serum levels were significantly higher. Gammaglobulin intravenously was well tolerated in all cases. Severe infections during the period of treatment were not observed.
 ...
PMID:[Gamma globulin in secondary antibody deficiency syndrome]. 9 44

One hundred and fifty-one eyes with anterior chamber implants and a best corrected visual acuity of at least 6/12 were studied to compare the predictive accuracies of the newer generation intraocular lens power calculation formulae. There was no statistically significant difference between the predictive accuracies of the SRK (Sanders-Retzlaff-Kraff), SRK II, SRK/Theoretical (SRK/T) and Holladay formulae. All these four formulae were more accurate than the Binkhorst II formula.
 ...
PMID:The newer generation intraocular lens power calculation formulae in anterior chamber implants. 128 14

The authors investigated the postoperative dioptric deviation from the calculated optic power of emetropic intraocular lenses by means of the formula SRK II without and with use of the individual regression constant A. Within the range of +/- 1.5 D the deviation varied for both methods in 87.7% of operated eyes; between -1.0 and +1.0 D the percentage of dioptric deviations without personalization was 66.2 and with the use of the individual constant A it was 73.8.
 ...
PMID:[The individual A constant in the SRK II formula]. 139 23

A retrospective biometric study was done on 132 patients with diffractive multifocal intraocular lenses. The two principal focal points induced by the intraocular lens were refracted for distance in each patient. The difference in diopters between the refractions was obtained, and the A constant (SRK formula series) and anterior chamber depth (ACD, Binkhorst formula) were calculated. Our results showed the A constant was 116.46. This value was consistent and not affected by the axial length of the eye in the 22mm to 24.5mm range. In patients who had emmetropia with the intraocular lens power implanted alone, the constant was equal to 116.3. The ACD was 3.94mm. This value was lower in shorter eyes and higher than 3.94mm in longer eyes. On the basis of the data obtained, when the SRK-II formula is used, an A constant of 116.4 should be used in preoperative biometric calculations.
 ...
PMID:Biometric aspects of diffractive multifocal intraocular lenses. 144 73

A principally new programme is described which overcomes the disadvantages of the usual calculation methods. It is based on the application of each surface of the optical system. The point for the anterior chamber lens is chosen in dependence on the anterior chamber depth; for the posterior chamber lens on the posterior surface of the eye lens. The programme is able to calculate 12 different cases. In each case calculations are made for intraocular lens power, aniseikonia and anisometropia. The calculations are made for possible emmetropia as well as for intended myopia or hypermetropia corresponding to the other eye. The programme can also be used to estimate the effect of mistakes made by measuring the single parameters, for instance: refraction, corneal curvature, eye length, anterior chamber depth. Compared to the SRK II-equation the results of the new programme are much more precise.
 ...
PMID:[A new program for calculating intraocular lenses]. 145 63

Presented is the evaluation of the usefulness of the SRK formula for the calculation of the power of the intraocular anterior chamber lens of Pannu type. This accuracy is characterised by the value of the postoperative deviation of refraction of the operated eye. It has been noticed that the value of this deviation is fluctuating in the early postoperative period. Its stabilization comes out not before the 6th-9th month after surgery. This points out to the necessity of calculating the correcting coefficient A for the SRK formula into the late postoperative period.
 ...
PMID:[The SRK formula for calculating the power of intraocular anterior-chamber lenses]. 145 68

When used for eyes with greater than average axial length (AXL), the SRK formula has been reported to have a tendency to yield more myopic refractions than those predicted. To further evaluate such findings, we studied 609 eyes with AXLs between 24.5 and 27.0 mm. Comparing the predicted with the actual refractions and calculating the range of errors, we found that the postoperative refractions were more myopic than predicted. Then, based on our evaluation of the relationship between the postoperative refractions and the powers of the implanted intraocular lenses (IOLs), we devised the following formula: R = 0.8 x (P - I) + 0.57 (P < .01) in which R = the postoperative refraction; P = the emmetropic IOL power; and I = the actual IOL power. Testing this modified SRK formula in 55 additional eyes, we found that the predicted postoperative refractions it yielded were more accurate than those calculated using five earlier formulas.
 ...
PMID:Modified SRK formula for axial myopia (24.5 mm < or = axial length < 27.0 mm). 148 Mar 68

Fifty consecutive patients who had cataract extraction and intraocular lens implantation with a can-opener anterior capsulotomy were compared to 50 patients who had a continuous tear capsulotomy and confirmed capsular bag lens placement. The actual versus the predicted postoperative refraction was calculated with both the SRK II and the Holladay lens power formulas. With both formulas, the capsulorhexis patients required a spectacle correction 0.43 (or 0.44) diopter greater than the can-opener patients when the same A-constant or surgeon factor was used. The recalculated A-constant was 118.23 for the can-opener patients and 118.76 for the capsulorhexis patients; the manufacturer's recommended A-constant was 118.3. The results were statistically significant.
 ...
PMID:Refractive effect of capsular bag lens placement with the capsulorhexis technique. 156 47


1 2 3 4 5 6 7 8 9 10 Next >>